BDRX BDRX
Company Profile ↓Company Overview
BDRX (BDRX) is a publicly traded company listed on with a market capitalization of $359.05B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -33.3%, profit CAGR 5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -33.33% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | 5.54% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -95.30% |
| 6 Months: | -80.49% |
| 3 Months: | -64.51% |
| 1 Month: | -40.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -33.3% CAGR over 5 years.
- Trading 97.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 699.00K | 381.00K | 0 | 0 |
| Cost of Revenue | - | 5.11M | 4.07M | 5.44M | 3.96M |
| Gross Profit | - | -4.41M | -3.69M | -5.44M | -3.96M |
| Operating Expenses | - | 4.52M | 4.33M | 3.76M | 4.68M |
| Operating Income | - | -8.93M | -8.01M | -9.20M | -8.64M |
| EBITDA | - | -8.09M | -7.16M | -5.56M | -6.07M |
| Interest Expense | - | 53.00K | 41.00K | 165.00K | 229.00K |
| Pretax Income | - | -8.49M | -7.49M | -5.98M | -6.49M |
| Tax Provision | - | -832.00K | -406.00K | -250.00K | -105.00K |
| Net Income | - | -7.66M | -7.08M | -5.73M | -6.38M |
| Diluted EPS | - | -775,000.00 | -10,000.00 | -500.00 | -0.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 5.53M | 10.54M | 14.78M | 18.18M |
| Current Assets | - | 4.69M | 7.03M | 8.81M | 12.44M |
| Cash & Equivalents | - | 2.84M | 5.97M | 1.67M | 8.53M |
| Inventory | - | - | - | - | - |
| Receivables | - | 329.00K | 0 | 11.00K | 35.00K |
| Total Liabilities | - | 2.36M | 5.86M | 6.46M | 6.77M |
| Current Liabilities | - | 1.90M | 5.57M | 5.03M | 6.13M |
| Long Term Debt | 0 | - | - | - | - |
| Total Debt | - | 624.00K | 464.00K | 727.00K | 61.00K |
| Total Equity | - | 3.16M | 4.68M | 8.32M | 11.40M |
| Shares Outstanding | - | 5.42M | 1.19B | 6.69B | 225.82B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -7.05M | -6.83M | -12.26M | -5.59M |
| Investing Cash Flow | - | -220.00K | -265.00K | -598.00K | -583.00K |
| Financing Cash Flow | - | 47.00K | 10.23M | 8.56M | 13.04M |
| Capital Expenditure | - | -62.00K | -263.00K | -774.00K | -691.00K |
| Free Cash Flow | - | -7.11M | -7.09M | -13.04M | -6.28M |
| Net Change in Cash | - | -7.22M | 3.13M | -4.30M | 6.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -631.2% | -967.5% | - | - |
| Operating Margin % | - | -1,277.8% | -2,103.4% | - | - |
| Net Margin % | - | -1,095.3% | -1,858.0% | - | - |
| ROE % | - | -242.1% | -151.3% | -68.8% | -56.0% |
| ROCE % | - | -246.4% | -161.2% | -94.4% | -71.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | - | 25 | $39 |
| 2 | Rhumbline Advisers | - | 4 | $6 |
| 3 | Sabby Management, LLC | - | 51.49K | $81.88K |
| 4 | Armistice Capital, LLC | - | 19.50K | $31.01K |
| 5 | Gamma Investing LLC | - | 1.20K | $1.91K |
| 6 | Allied Private Wealth LLC | - | 489 | $777 |
| 7 | SBI Securities Co., Ltd. | - | 29 | $46 |
| 8 | Hilton Head Capital Partners, LLC | - | 6 | $9 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDRX
European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading
European equities traded in the US as American depositary receipts were edging higher late Wednesday
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European equities traded in the US as American depositary receipts started the week off lower late M
Result of General Meeting
July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment …
European Equities Traded in US as ADRs Ease in Wednesday Trading
European equities traded in the US as American depositary receipts eased late Wednesday morning with
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
July 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatme…
European Equities Traded in US as ADRs Ease in Tuesday Trading
European equities traded in the US as American depositary receipts eased late Tuesday morning with t
BDRX — Frequently Asked Questions
What is the current share price of BDRX?
As of 2026-08-05 17:25 PDT, BDRX trades at $1.59 on NASDAQ/NYSE. Its 52-week range is $1.32 to $54.50.
What is the market capitalisation of BDRX?
BDRX has a market capitalisation of $359.05B on NASDAQ/NYSE.
What is the P/E ratio of BDRX?
BDRX trades at a trailing price-to-earnings (P/E) ratio of -3.18.
What is the return on equity (ROE) of BDRX?
BDRX has a return on equity (ROE) of -55.98%. Its return on capital employed (ROCE) is -51.95%.
Is BDRX a good stock to buy?
This page provides a data-driven analysis of BDRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.